Page 98 of 439: studies 971 to 980 of 4,389, newest first. Back to the psilocybin overview
May 2, 2024 Hanna Brancaccio
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current treatment options include behavioral therapies and medications. In this review, we explored psilocybin’s efficacy in treating SUD and AUD. Methods: Key terms were used to search databases to identify articles that addressed psilocybin in the...
Social Work May 2, 2024 Claire Parker, Bethany Wood 2 citations
Abstract This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD,...
Drug and Alcohol Dependence May 1, 2024 Joseph J Palamar, Nicole D. Fitzgerald, Thomas H Carr et al. 9 citations
Psilocybin, the principle psychoactive component in "shrooms", is regaining acceptance in therapeutic settings, leading to media coverage of medical benefits associated with use. Possession is also becoming increasingly decriminalized throughout the United States. There is a lack of data on prevalence of shroom use, but trends in law enforcement seizure data can provide one indicator of shroom...
Journal of Adolescent Health May 1, 2024 Rita Farah, Abigail F Kerns, Austin C Murray et al. 18 citations
We describe trends in psilocybin exposures among adolescents and young adults as reported to US poison centers over the past decade. We queried the National Poison Data System for cases involving psilocybin during January 1, 2013-December 31, 2022. Persons aged 13-25 years were included. We examined exposures to psilocybin by demographics, clinical effects, level of care, and medical outcome....
BMJ May 1, 2024 Athina-Marina Metaxa, Mike Clarke 78 citations
Abstract Objective To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. Design Systematic review and meta-analysis. Data sources Five electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four...
Acta Crystallographica. Section E, Crystallographic Communications May 1, 2024 Matthias Zeller, Stephan Parent, Nate Schultheiss
The title compound, C12H16N2O, is a hy-droxy-substituted mono-amine alkaloid, and the primary metabolite of the naturally occurring psychedelic compound psilocybin. Crystalline forms of psilocin are known, but their characterization by single-crystal structure analysis is limited. Herein, two anhydrous polymorphic forms (I and II) of psilocin are described. The crystal structure of polymorphic...
Biological Psychiatry April 29, 2024 Joshua S. Siegel, Subha Subramanian, Nico U.f. Dosenbach et al. 14 citations
1 Summary The relationship between the acute effects of psychedelics and their persisting neurobiological and psychological effects is poorly understood. Here, we tracked brain changes with longitudinal precision functional mapping in healthy adults before, during, and for up to 3 weeks after oral psilocybin and methylphenidate (17 MRI visits per participant) and again 6+ months later....
Frontiers in Pharmacology April 29, 2024 Jan Thomann, Oliver V Stoeckmann, Deborah Rudin et al. 52 citations
In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT 2A receptor. Psilocin primarily undergoes glucuronidation or conversion to 4-hydroxyindole-3-acetic acid (4-HIAA). Herein, we investigated psilocybin’s metabolic pathways in vitro and in vivo , conducting a thorough analysis of the enzymes involved. Metabolism studies were...
Journal of Psychopharmacology April 28, 2024 Xiangting Zhao, Yingjie Du, Yishan Yao et al. 53 citations
Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. Aims: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate...
Molecular Psychiatry April 27, 2024 Kyna Conn, L K Milton, K Huang et al. 44 citations
Abstract Psilocybin has shown promise for alleviating symptoms of depression and is currently in clinical trials for the treatment of anorexia nervosa (AN), a condition that is characterised by persistent cognitive inflexibility. Considering that enhanced cognitive flexibility after psilocybin treatment is reported to occur in individuals with depression, it is plausible that psilocybin could...